Ask AI
Optimizing ALL Treatment
Expert Guidance on Optimizing Treatment Strategies for Acute Lymphoblastic Leukemia

Released: April 16, 2020

Activity

Progress
1
Course Completed

In this module, Amir T. Fathi, MD, reviews patient cases and provides an overview of the latest treatment options for patients with acute lymphoblastic leukemia (ALL), including antibody–drug conjugate (ADC), bispecific T-cell engager (BiTE), and CAR T-cell therapy.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset; they can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once before the discussion that informs the best choice and then again after that specific discussion. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions. 

If you are a practicing clinician, how many patients with ALL do you provide care for in a typical month?
In your current clinical practice, what therapy would you recommend for this patient?
In a discussion with the newest members of your clinical team, which of the following management approaches would you indicate is NOT appropriate for a patient with B-cell ALL who is experiencing severe veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) following an alloSCT?
In your current clinical practice, what therapy would you recommend for this patient?